Applied Therapeutics’ Pivotal Galactosemia Product Stalls, Confirming Analyst Concerns
Executive Summary
Analysts’ fears have been confirmed as a US FDA demand for clinical outcomes data has forced Applied Therapeutics to delay a planned filing for its lead product candidate, AT-007, in the rare disease galactosemia based on biomarker data alone.
You may also be interested in...
Applied Therapeutics Takes Strong Swipe At SORD With Govorestat
Govorestat could soon be filed for a second indication after impressing as a potential treatment for SORD deficiency, one of the most common forms of recessive hereditary neuropathy for which there are no approved therapies.
Stock Watch: 2022 Starts Badly For Biotech
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.